$8.18
1.27% today
Nasdaq, Feb 28, 04:49 pm CET
ISIN
US3984384087
Symbol
GRFS
Sector
Industry

Grifols, S.A. Sponsored ADR Class B Stock price

$8.28
+1.04 14.36% 1M
-0.48 5.48% 6M
+0.84 11.29% YTD
-1.02 10.97% 1Y
-4.08 33.01% 3Y
-15.20 64.74% 5Y
-8.08 49.38% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.34 4.28%
ISIN
US3984384087
Symbol
GRFS
Sector
Industry

Key metrics

Market capitalization $2.13b
Enterprise Value $15.36b
P/E (TTM) P/E ratio 33.01
P/B ratio (TTM) P/B ratio 0.94
Cash position $719.79m
P/E forward 21.60
P/S forward 0.27
EV/Sales forward 2.04
Short interest 0.40%

Is Grifols, S.A. Sponsored ADR Class B a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Grifols, S.A. Sponsored ADR Class B Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

1x Buy
25%
2x Hold
50%
1x Sell
25%

Analyst Opinions

4 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

Buy
25%
Hold
50%
Sell
25%

Financial data from Grifols, S.A. Sponsored ADR Class B

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,970 1,970
13% 13%
100%
- Direct Costs 1,171 1,171
11% 11%
59%
798 798
16% 16%
41%
- Selling and Administrative Expenses 232 232
10% 10%
12%
- Research and Development Expense 97 97
0% 0%
5%
470 470
23% 23%
24%
- Depreciation and Amortization 119 119
2% 2%
6%
EBIT (Operating Income) EBIT 351 351
33% 33%
18%
Net Profit 57 57
12% 12%
3%

In millions USD.

Don't miss a Thing! We will send you all news about Grifols, S.A. Sponsored ADR Class B directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Grifols, S.A. Sponsored ADR Class B Stock News

Positive
Seeking Alpha
about 22 hours ago
Grifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company's revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Grifols' valuation is attractive, with a potential ...
Positive
Reuters
about 24 hours ago
Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost more than 30% of its market value.
Positive
Reuters
2 days ago
Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion euros, up 10.2% from a year earlier and above its target for 7% sales growth.
More Grifols, S.A. Sponsored ADR Class B News

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Head office Spain
CEO Nacho Abia
Employees 23,744
Founded 1940
Website www.grifols.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today